MASSACHUSETTS GENERAL HOSPITAL
Department of Pharmacy
Department of Nursing
Critical Care
| Generic Name: | Cytomegalovirus immune globulin intravenous (human) |
| Trade Name: | CMV - IGIV |
| Action: | Immunoglobulin with relatively high concentration of antibodies directed against CMV |
| Indications: | Attenuation of primary cytomegalovirus disease associated with transplantation. Specifically indicated for transplant recipients who are seronegative for CMV and who receive an organ from CMV seropositive donor. |
| Administration Guidelines: | Maximum recommended dosage per infusion - 150 mg/kg |
| Administration Preparation | - reconstitute powder with 50 ml sterile
H20 - Do not shake the vials...avoid foaming - Allow 30 minutes to dissolve |
| Infusion | - I.V. administration via
macro-infusion device with vented tubing or with a syringe
based, variable flow continuous microinfusion pump.
- Rate of administration is calculated by weight and increased in increments over a determined amount of time (*refer to attached administration guidelines) - *Do not exceed a maximum rate of > 75 ml/hr. |
| Special Considerations: | - *Vital signs should be done
pre-infusion, midway and post-infusion, as well as before any rate increase. - Infusion should begin within 6 hours of reconstitution - Obtained from blood bank. |
| Precautions and Side Effects: | - If a patient develops minor
side-effects, such as flushing, nausea, back pain, muscle cramps, slow down
infusion. - Hypotension |